多学会多专业关于皮质类固醇注射与流感及COVID-19疫苗接种的立场声明
该多学会多专业立场声明针对慢性疼痛患者接受皮质类固醇注射(CSI)与流感及COVID-19疫苗接种之间的安全间隔提出循证建议,采用改良Delphi流程达成共识(≥75%同意)。建议非紧急情况下CSI应在疫苗接种前或后至少1周进行;健康患者经知情同意可不间隔7天;非健康患者需共同决策讨论疫苗效果减弱风险。
要点
- 非紧急CSI建议在疫苗接种前或后至少间隔1周。
- 健康患者经知情讨论和同意后可不要求7天间隔。
- 非健康患者需共同决策讨论疫苗效果减弱和感染风险。
核心结论
- 对于非紧急适应症,若疫苗已接种或计划接种,CSI应在疫苗接种前或后至少1周进行。
- 健康患者经知情讨论和同意后,CSI或疫苗接种可不要求7天间隔。
- 非健康患者的共同决策应包括讨论疫苗效果减弱以及流感或COVID-19感染的可能性。
研究设计与样本
- 由美国区域麻醉和疼痛医学学会董事会及其他同意参与的学会批准制定,采用改良Delphi流程达成共识(≥75%同意),并遵循改良版美国预防服务工作组证据分级和推荐强度。
主要发现
- 所有声明推荐在四轮讨论后经所有参与者批准,并经参与学会的实践指南委员会和董事会批准。
关键数值与推荐
- 非紧急情况下,CSI应在疫苗接种前或后至少1周进行。
- 健康患者经知情讨论和同意后,可不要求7天间隔。
- 非健康患者需共同决策讨论疫苗效果减弱和感染风险。
临床怎么用
- 临床中应根据患者健康状况和疫苗计划,与患者讨论并决定CSI与流感或COVID-19疫苗接种的间隔。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Corticosteroid injections (CSIs) are widely employed for chronic pain. These injections include peripheral nerve blocks and trigger point injections, injections of large appendicular joints, the axial facet and sacroiliac joints, and the epidural space. These injections may be performed in patients who have been recently vaccinated or plan to be vaccinated. This multisociety multispecialty position statement aims to develop evidence-based statements and recommendations (SRs) on the safe interval between CSIs and COVID-19 and influenza vaccine administration. METHODS: Development of the position statement was approved by the American Society of Regional Anesthesia and Pain Medicine Board of Directors and several other societies that agreed to participate. The scope of the SRs was agreed on to include the efficacy of COVID-19 and influenza vaccines, adverse events related to the CSIs, specifically the effect of CSIs on the hypothalamic-pituitary axis, incidence of COVID-19 in patients who had CSIs during the pandemic, incidence of influenza in patients who had CSIs during the influenza season, and recommend a reasonable interval between CSIs and COVID-19 and influenza vaccination 20 mg/day of prednisone s. Experts were assigned topics to perform a comprehensive literature review and draft SRs, which were refined and voted for consensus (≥75% agreement) using a modified Delphi process. A modified version of the US Preventive Services Task Force grading of evidence and strength of recommendation was followed. RESULTS: All SRs were approved by all participants after four rounds of discussion. The Practice Guidelines Committees and Boards of Directors of the participating societies also approved all SRs. If a vaccine has been recently administered or planned, then for non-urgent indications, the CSI should be offered at least 1 week before or after vaccine administration. For healthy patient(s), CSI, or vaccine administration may be performed without a 7-day interval after informed discussion with the patient and consent regarding the risk of blunted vaccine efficacy. For non-healthy patients, shared decision-making should include discussion of diminished vaccine effectiveness and the possibility of influenza or COVID-19 infection. CONCLUSIONS: In this position statement, we provide recommendations on the optimal timing between CSIs and COVID-19 or influenza vaccine.
引用
- Benzon HT, FitzGerald J, Flaherty JP, et al. Multisociety multispecialty position statement on corticosteroid injections and influenza and COVID-19 vaccine administration. Reg Anesth Pain Med. 2026. PMID: 41760373. doi:10.1136/rapm-2025-107556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。